Connect public, paid and private patent data with Google Patents Public Datasets

Traitement de la gastroparesie

Info

Publication number
WO2003087139A2
WO2003087139A2 PCT/US2003/008457 US0308457W WO2003087139A2 WO 2003087139 A2 WO2003087139 A2 WO 2003087139A2 US 0308457 W US0308457 W US 0308457W WO 2003087139 A2 WO2003087139 A2 WO 2003087139A2
Authority
WO
Grant status
Application
Patent type
Prior art keywords
glp
oh
val
gastroparesis
glu
Prior art date
Application number
PCT/US2003/008457
Other languages
English (en)
Other versions
WO2003087139A3 (fr )
Inventor
Joseph Anthony Jakubowski
Thurman Dwight Mckinney
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons

Abstract

Cette invention a trait à l'utilisation de composés à base de peptides-1 du type glucagon GLP-1 pour le traitement de la gastroparésie. Les patients atteints de gastroparésie connaissent un retard de la vidange gastrique. On peut utiliser les composés de GLP-1 pour réguler cette vidange gastrique.
PCT/US2003/008457 2002-04-10 2003-03-27 Traitement de la gastroparesie WO2003087139A3 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US37165002 true 2002-04-10 2002-04-10
US60/371,650 2002-04-10

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CA 2480858 CA2480858A1 (fr) 2002-04-10 2003-03-27 Traitement de la gastroparesie
US10508762 US20050164925A1 (en) 2002-04-10 2003-03-27 Treatment of gastroparesis
KR20047016025A KR20040098063A (ko) 2002-04-10 2003-03-27 위마비의 치료
EP20030716707 EP1496924A4 (fr) 2002-04-10 2003-03-27 Traitement de la gastroparesie
JP2003584094A JP2005530732A (ja) 2002-04-10 2003-03-27 胃不全麻痺の治療

Publications (2)

Publication Number Publication Date
WO2003087139A2 true true WO2003087139A2 (fr) 2003-10-23
WO2003087139A3 true WO2003087139A3 (fr) 2004-01-08

Family

ID=29250714

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/008457 WO2003087139A3 (fr) 2002-04-10 2003-03-27 Traitement de la gastroparesie

Country Status (7)

Country Link
US (1) US20050164925A1 (fr)
JP (1) JP2005530732A (fr)
KR (1) KR20040098063A (fr)
CN (1) CN1735423A (fr)
CA (1) CA2480858A1 (fr)
EP (1) EP1496924A4 (fr)
WO (1) WO2003087139A3 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028516A2 (fr) * 2003-09-19 2005-03-31 Novo Nordisk A/S Nouvelles etiquettes d'affinite pour les proteines plasmiques
WO2005027978A2 (fr) * 2003-09-19 2005-03-31 Novo Nordisk A/S Nouveaux derives de glp-1
WO2011136361A1 (fr) 2010-04-30 2011-11-03 株式会社 三和化学研究所 Peptide permettant d'améliorer la stabilité in vivo d'une substance physiologiquement active ou analogues et substance physiologiquement active et analogues présentant une amélioration de la stabilité in vivo
EP2573111A1 (fr) * 2006-04-20 2013-03-27 Amgen Inc. Composés GLP-1
US8513192B2 (en) 2009-01-22 2013-08-20 Novo Nordisk A/S Stable growth hormone compounds resistant to proteolytic degradation
US8536122B2 (en) 2005-03-18 2013-09-17 Novo Nordisk A/S Acylated GLP-1 compounds
US8603972B2 (en) 2005-03-18 2013-12-10 Novo Nordisk A/S Extended GLP-1 compounds
US8779109B2 (en) 2010-01-22 2014-07-15 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
US8865868B2 (en) 2008-08-06 2014-10-21 Novo Nordisk Healthcare Ag Conjugated proteins with prolonged in vivo efficacy
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8666495B2 (en) 1999-03-05 2014-03-04 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
US9101765B2 (en) 1999-03-05 2015-08-11 Metacure Limited Non-immediate effects of therapy
US8792985B2 (en) 2003-07-21 2014-07-29 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
US9821158B2 (en) 2005-02-17 2017-11-21 Metacure Limited Non-immediate effects of therapy
US8612016B2 (en) 2004-08-18 2013-12-17 Metacure Limited Monitoring, analysis, and regulation of eating habits
EP1880298B1 (fr) 2005-02-17 2016-07-13 Metacure Limited Chargeur dote de moyens de transfert de donnees
EP1890763A4 (fr) 2005-06-02 2017-05-03 Metacure Ltd Implantation de fils gi
WO2007080595A3 (fr) 2006-01-12 2009-04-16 Yuval Elovici Ensembles d'électrodes, outils et procédés pour une implantation sur une paroi gastrique
US8265758B2 (en) * 2005-03-24 2012-09-11 Metacure Limited Wireless leads for gastrointestinal tract applications
US8442841B2 (en) * 2005-10-20 2013-05-14 Matacure N.V. Patient selection method for assisting weight loss
US8295932B2 (en) 2005-12-05 2012-10-23 Metacure Limited Ingestible capsule for appetite regulation
WO2008139463A3 (fr) * 2007-05-09 2010-01-28 Metacure Ltd. Analyse et régulation d'une absorption de nourriture
US8423130B2 (en) * 2008-05-09 2013-04-16 Metacure Limited Optimization of thresholds for eating detection
US8642548B2 (en) * 2009-08-07 2014-02-04 Mannkind Corporation Val (8) GLP-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
US8934975B2 (en) 2010-02-01 2015-01-13 Metacure Limited Gastrointestinal electrical therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981488A (en) * 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US20010046956A1 (en) * 2000-04-27 2001-11-29 Hadcock John R. Methods of treating obesity using a neurotensin receptor ligand

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US5981488A (en) * 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
US20010046956A1 (en) * 2000-04-27 2001-11-29 Hadcock John R. Methods of treating obesity using a neurotensin receptor ligand

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1496924A2 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028516A2 (fr) * 2003-09-19 2005-03-31 Novo Nordisk A/S Nouvelles etiquettes d'affinite pour les proteines plasmiques
WO2005027978A2 (fr) * 2003-09-19 2005-03-31 Novo Nordisk A/S Nouveaux derives de glp-1
WO2005027978A3 (fr) * 2003-09-19 2005-05-19 Novo Nordisk As Nouveaux derives de glp-1
WO2005028516A3 (fr) * 2003-09-19 2005-09-29 Florencio Zaragoza Doerwald Nouvelles etiquettes d'affinite pour les proteines plasmiques
US7897560B2 (en) 2003-09-19 2011-03-01 Novo Nordisk A/S Plasma protein affinity tags
EP2932981A3 (fr) * 2003-09-19 2016-02-24 Novo Nordisk A/S Nouveaux dérivés GLP-1 se liant à l'albumine
US8603972B2 (en) 2005-03-18 2013-12-10 Novo Nordisk A/S Extended GLP-1 compounds
US8536122B2 (en) 2005-03-18 2013-09-17 Novo Nordisk A/S Acylated GLP-1 compounds
EP2573111A1 (fr) * 2006-04-20 2013-03-27 Amgen Inc. Composés GLP-1
US8865868B2 (en) 2008-08-06 2014-10-21 Novo Nordisk Healthcare Ag Conjugated proteins with prolonged in vivo efficacy
US8513192B2 (en) 2009-01-22 2013-08-20 Novo Nordisk A/S Stable growth hormone compounds resistant to proteolytic degradation
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
US8779109B2 (en) 2010-01-22 2014-07-15 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
US9695226B2 (en) 2010-01-22 2017-07-04 Novo Nordisk Healthcare Ag Growth hormones with prolonged in-vivo efficacy
WO2011136361A1 (fr) 2010-04-30 2011-11-03 株式会社 三和化学研究所 Peptide permettant d'améliorer la stabilité in vivo d'une substance physiologiquement active ou analogues et substance physiologiquement active et analogues présentant une amélioration de la stabilité in vivo

Also Published As

Publication number Publication date Type
CN1735423A (zh) 2006-02-15 application
KR20040098063A (ko) 2004-11-18 application
JP2005530732A (ja) 2005-10-13 application
EP1496924A4 (fr) 2007-05-30 application
EP1496924A2 (fr) 2005-01-19 application
US20050164925A1 (en) 2005-07-28 application
WO2003087139A3 (fr) 2004-01-08 application
CA2480858A1 (fr) 2003-10-23 application

Similar Documents

Publication Publication Date Title
Drucker Biologic actions and therapeutic potential of the proglucagon-derived peptides
Haak et al. Lower within‐subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes
Vella et al. Effect of glucagon-like peptide 1 (7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes.
Hvidberg et al. Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man
Rosenstock et al. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. US Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
US6358924B1 (en) GLP-1 formulations
Richter et al. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes
McKeage et al. Insulin glargine
US6852690B1 (en) Method and composition for enhanced parenteral nutrition
US20050148497A1 (en) Method for administering glp-1 molecules
US6136784A (en) Amylin agonist pharmaceutical compositions containing insulin
Gillies et al. Insulin glargine
US20060063719A1 (en) Methods for treating diabetes
US20070032420A1 (en) Treating diabetes with glucagon-like peptide-1 secretagogues
Morley et al. Amylin decreases food intake in mice
US5124314A (en) Pharmaceutical compositions containing amylin
Näslund et al. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects
US6143718A (en) Treatment of Type II diabetes mellutis with amylin agonists
Purnell et al. Weight effect of current and experimental drugs for diabetes mellitus
US7056887B2 (en) Treatment of acute coronary syndrome with GLP-1
WO1997007814A1 (fr) Composition destinee a une alimentation parenterale amelioree et procede correspondant
Chapman et al. Insulin aspart
Nadkarni et al. Regulation of glucose homeostasis by GLP-1
WO2004064862A1 (fr) Insuline a action prolongee pouvant reduire la morbidite et la mortalite cardiovasculaires chez des patients prediabetiques et des patients atteints de diabete non insulino-dependant
WO2003035099A1 (fr) Melanges biphasiques de glp-1 et d'insuline

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1-2004-501617

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 10508762

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003220403

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2480858

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 535684

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 200408111

Country of ref document: ZA

Ref document number: 2004/08111

Country of ref document: ZA

Ref document number: P20040939A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 373658

Country of ref document: PL

Ref document number: 1020047016025

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20038080079

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2003584094

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003716707

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020047016025

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003716707

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 535684

Country of ref document: NZ

WWR Wipo information: refused in national office

Ref document number: 1020047016025

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2003716707

Country of ref document: EP